Opinion|Videos|October 23, 2023

Amivantamab for Patients With NSCLC and an EGFR Exon 20 Mutation

Author(s)Misako Nagasaka, MD, PhD, Kristen Neumann, DNP, FNP-C

Kristen Neumann, DNP, FNP-C, emphasizes the efficacy of the drug amivantamab for patients with EGFR exon 20 mutations, explaining the challenges of unique skin rashes, but highlighting the importance of teamwork in effectively managing and treating these adverse skin effects.

Episodes in this series

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 1 Managing Treatment-Related Rashes in Patients With EGFR-Mutated NSCLC

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 2 Managing Treatment-Related Diarrhea in Patients With EGFR-Mutated NSCLC

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 3 Implementing Dose Reductions and Dose Holds in Patients With EGFR-Mutated NSCLC Receiving TKIs

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 4 Multidisciplinary Management of Treatment-Related Adverse Events in Patients With EGFR-Mutated NSCLC

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 5 Amivantamab for Patients With NSCLC and an EGFR Exon 20 Mutation

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 6 Educating Patients and Clinical Staff on Infusion-Related Adverse Reactions Seen With Amivantamab in NSCLC With EGFR Exon 20 Mutations

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 7 Future Perspectives in the Treatment and Management of Patients With EGFR-Mutated NSCLC

EP. 8 Approaches to Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)

EP. 8 Approaches to Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)

EP. 9 EGFR Mutations in Patients With NSCLC

EP. 9 EGFR Mutations in Patients With NSCLC

EP. 10 Adverse Effect Management in Non–Small Cell Lung Cancer Treatment

EP. 10 Adverse Effect Management in Non–Small Cell Lung Cancer Treatment

EP. 11 Patient Case Presentation: A 59-Year-Old Man With EGFR-Mutant NSCLC

EP. 11 Patient Case Presentation: A 59-Year-Old Man With EGFR-Mutant NSCLC

EP. 12 The Future of Treatment for EGFR TKI Resistance in EGFR-Mutant NSCLC

EP. 12 The Future of Treatment for EGFR TKI Resistance in EGFR-Mutant NSCLC

Next steps for research in lung cancer may include identifying how the gut microbiome impacts responses and adverse effects associated with treatment, says Misako Nagasaka, MD, PhD.

EP. 13 Multidisciplinary Care, Approval Updates, and Future Research in NSCLC

EP. 14 Treatment Approaches for Patients With EGFR-Mutant NSCLC

EP. 14 Treatment Approaches for Patients With EGFR-Mutant NSCLC

EP. 15 Common Adverse Events Seen With EGFR TKIs in EGFR-Mutant NSCLC

EP. 15 Common Adverse Events Seen With EGFR TKIs in EGFR-Mutant NSCLC

EP. 16 Approaches to Managing Patients With EGFR-Mutant NSCLC and EGFR TKI Resistance

EP. 16 Approaches to Managing Patients With EGFR-Mutant NSCLC and EGFR TKI Resistance

EP. 17 Patient Case Presentation: A 69-Year-Old Man With NSCLC With EGFR Exon 20 Insertion Mutations

EP. 17 Patient Case Presentation: A 69-Year-Old Man With NSCLC With EGFR Exon 20 Insertion Mutations

EP. 18 Management Strategies for Adverse Events Seen With Amivantamab in NSCLC With EGFR Exon 20 Insertion Mutations

EP. 18 Management Strategies for Adverse Events Seen With Amivantamab in NSCLC With EGFR Exon 20 Insertion Mutations

EP. 19 The Future of Treatment for NSCLC With EGFR Exon 20 Insertion Mutations

EP. 19 The Future of Treatment for NSCLC With EGFR Exon 20 Insertion Mutations

EP. 20 Unmet Needs and Future Perspectives in NSCLC Treatment

EP. 20 Unmet Needs and Future Perspectives in NSCLC Treatment

EP. 21 New Lung Cancer Treatment Options Combine Neoadjuvant and Adjuvant Therapies

EP. 21 New Lung Cancer Treatment Options Combine Neoadjuvant and Adjuvant Therapies

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

David R. Gandara, MD, explains what makes KRAS G12C biologically distinct from other KRAS subtypes in NSCLC immunotherapy response.

September 23rd, 2026

Why KRAS G12C May Drive a Survival Benefit With Cemiplimab in NSCLC

David R. Gandara, MD, explains what makes KRAS G12C biologically distinct from other KRAS subtypes in NSCLC immunotherapy response.

Xiuning Le, MD, PhD, weighs sevabertinib against zongertinib and trastuzumab deruxtecan in HER2-mutant non–small cell lung cancer.

September 23rd, 2026

How Sevabertinib Stacks Up Against Other HER2-Directed NSCLC Options

Xiuning Le, MD, PhD, weighs sevabertinib against zongertinib and trastuzumab deruxtecan in HER2-mutant non–small cell lung cancer.

Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.

September 22nd, 2026

Distinguishing HER2 Mutations From Amplification in NSCLC Testing

Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.

Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.

September 20th, 2026

Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026

Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.

Subcutaneous amivantamab is safer and more convenient for patients compared with the intravenous formulation, according to Misako Nagasaka, MD, PhD.

September 18th, 2026

Subcutaneous Amivantamab Combo is a “Clear” New Standard in EGFR+ NSCLC

Subcutaneous amivantamab is safer and more convenient for patients compared with the intravenous formulation, according to Misako Nagasaka, MD, PhD.

3D Rendered Medical Illustration of Male Anatomy - Lung Cancer. | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

September 17th, 2026

PD-1/VEGF Bispecific Antibody Receives FDA Fast Track Designation in NSCLC

Investigators are evaluating cesalatamig among patients with advanced cancer in the international phase 1/2 BiPAVE-001 trial.

KST-6051 Receives Fast Track Designation in KRAS-Mutant Solid Tumors: © barinovalena - stock.adobe.com

September 17th, 2026

KST-6051 Receives FDA Fast Track Designation in KRAS-Mutant Solid Tumors

The FDA granted fast track designation to the oral pan-KRAS inhibitor KST-6051 for patients with KRAS-mutant advanced or metastatic solid tumors.

FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC

September 17th, 2026

FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC

Based on updated data from the TRUST-1 trial, a sNDA for taletrectinib has been approved by the FDA for patients with TKI-naive ROS1+ NSCLC.

Trending on CancerNetwork

Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs

PANXEON Liquid Biopsy Demonstrates Potential for Detecting Early Pancreatic Cancer

Rusfertide Earns Category 1 NCCN Recommendation in Polycythemia Vera

AdenoVerse Platform Receives FDA Designation for HPV-Associated Cancers

Novel Monoclonal Antibody Wins FDA Fast Track Designation in High-Risk MDS